Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000165456 | SCV000216186 | likely benign | Hereditary cancer-predisposing syndrome | 2014-09-05 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV000204529 | SCV000259847 | likely benign | Neurofibromatosis, type 1 | 2025-01-23 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001570293 | SCV001794564 | likely benign | not provided | 2020-10-30 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000165456 | SCV002527378 | likely benign | Hereditary cancer-predisposing syndrome | 2021-09-16 | criteria provided, single submitter | curation | |
Genome- |
RCV000204529 | SCV002561972 | likely benign | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492660 | SCV002800069 | likely benign | Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis | 2021-11-24 | criteria provided, single submitter | clinical testing |